Longtime CEO of drug maker GSK to step down next year


Save Story

Estimated read time: Less than a minute

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.

LONDON (AP) — The head of pharmaceutical company GlaxoSmithKline, Andrew Witty, has announced he will leave after eight years as CEO.

The search for a successor comes amid months of pressure from some investors, who had wanted the diverse company to be broken up.

The company, known as GSK, said in a statement Thursday that Witty, who first joined the company in 1985, believes "this will be the right time for a new leader to take over." The move is effective in March 2017.

Like many big pharmaceutical companies, GSK has struggled to see off the challenge of generic drugmakers and come up with new blockbuster drugs to replace medicines with expiring patents.

It has also faced other challenges. Britain's competition authority has fined GSK 37.6 million pounds ($54.5 million) for stalling the potential entry of generic competitors of anti-depressant drug Seroxat into the marketplace.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Most recent Business stories

Related topics

The Associated Press
    KSL.com Beyond Series
    KSL.com Beyond Business

    KSL Weather Forecast

    KSL Weather Forecast
    Play button